Colon Cancer-Pipeline Review, H1 2016

Colon Cancer-Pipeline Review, H1 2016


  • Products Id :- GMDHC7965IDB
  • |
  • Pages: 672
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Colon Cancer-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Colon Cancer-Pipeline Review, H1 2016', provides an overview of the Colon Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Colon Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Colon Cancer

The report reviews pipeline therapeutics for Colon Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Colon Cancer therapeutics and enlists all their major and minor projects

The report assesses Colon Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Colon Cancer

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Colon Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Colon Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 8

Colon Cancer Overview 9

Therapeutics Development 10

Colon Cancer-Therapeutics under Development by Companies 12

Colon Cancer-Therapeutics under Investigation by Universities/Institutes 22

Colon Cancer-Pipeline Products Glance 25

Colon Cancer-Products under Development by Companies 29

Colon Cancer-Products under Investigation by Universities/Institutes 41

Colon Cancer-Companies Involved in Therapeutics Development 45

Colon Cancer-Therapeutics Assessment 165

Drug Profiles 189

Colon Cancer-Dormant Projects 614

Colon Cancer-Discontinued Products 632

Colon Cancer-Product Development Milestones 633

Appendix 644

List of Figures

Number of Products under Development for Colon Cancer, H1 2016 37

Number of Products under Development for Colon Cancer-Comparative Analysis, H1 2016 38

Number of Products under Development by Companies, H1 2016 39

Number of Products under Investigation by Universities/Institutes, H1 2016 49

Comparative Analysis by Clinical Stage Development, H1 2016 53

Comparative Analysis by Early Stage Products, H1 2016 54

Assessment by Monotherapy Products, H1 2016 192

Assessment by Combination Products, H1 2016 193

Number of Products by Top 10 Targets, H1 2016 194

Number of Products by Stage and Top 10 Targets, H1 2016 194

Number of Products by Top 10 Mechanism of Actions, H1 2016 204

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 204

Number of Products by Top 10 Routes of Administration, H1 2016 212

Number of Products by Stage and Top 10 Routes of Administration, H1 2016 212

Number of Products by Top 10 Molecule Types, H1 2016 214

Number of Products by Stage and Top 10 Molecule Types, H1 2016 214

List of Tables

Number of Products under Development for Colon Cancer, H1 2016 37

Number of Products under Development for Colon Cancer-Comparative Analysis, H1 2016 38

Number of Products under Development by Companies, H1 2016 39

Number of Products under Development by Companies, H1 2016 (Contd..1) 40

Number of Products under Development by Companies, H1 2016 (Contd..2) 41

Number of Products under Development by Companies, H1 2016 (Contd..3) 42

Number of Products under Development by Companies, H1 2016 (Contd..4) 43

Number of Products under Development by Companies, H1 2016 (Contd..5) 44

Number of Products under Development by Companies, H1 2016 (Contd..6) 45

Number of Products under Development by Companies, H1 2016 (Contd..7) 46

Number of Products under Development by Companies, H1 2016 (Contd..8) 47

Number of Products under Development by Companies, H1 2016 (Contd..9) 48

Number of Products under Investigation by Universities/Institutes, H1 2016 49

Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 50

Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 51

Comparative Analysis by Late Stage Development, H1 2016 52

Comparative Analysis by Clinical Stage Development, H1 2016 53

Comparative Analysis by Early Stage Development, H1 2016 54

Comparative Analysis by Unknown Stage Development, H1 2016 55

Products under Development by Companies, H1 2016 56

Products under Development by Companies, H1 2016 (Contd..1) 57

Products under Development by Companies, H1 2016 (Contd..2) 58

Products under Development by Companies, H1 2016 (Contd..3) 59

Products under Development by Companies, H1 2016 (Contd..4) 60

Products under Development by Companies, H1 2016 (Contd..5) 61

Products under Development by Companies, H1 2016 (Contd..6) 62

Products under Development by Companies, H1 2016 (Contd..7) 63

Products under Development by Companies, H1 2016 (Contd..8) 64

Products under Development by Companies, H1 2016 (Contd..9) 65

Products under Development by Companies, H1 2016 (Contd..10) 66

Products under Development by Companies, H1 2016 (Contd..11) 67

Products under Investigation by Universities/Institutes, H1 2016 68

Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 69

Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 70

Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 71

Colon Cancer-Pipeline by ACF Pharmaceuticals, LLC, H1 2016 72

Colon Cancer-Pipeline by Adgero Biopharmaceuticals, Inc., H1 2016 73

Colon Cancer-Pipeline by Aduro BioTech, Inc., H1 2016 74

Colon Cancer-Pipeline by Advanced Proteome Therapeutics Corporation, H1 2016 75

Colon Cancer-Pipeline by Advenchen Laboratories, LLC, H1 2016 76

Colon Cancer-Pipeline by Agenus, Inc., H1 2016 77

Colon Cancer-Pipeline by AGV Discovery, SAS, H1 2016 78

Colon Cancer-Pipeline by AIMM Therapeutics B.V., H1 2016 79

Colon Cancer-Pipeline by Ambrx, Inc., H1 2016 80

Colon Cancer-Pipeline by Anavex Life Sciences Corp., H1 2016 81

Colon Cancer-Pipeline by AndroScience Corporation, H1 2016 82

Colon Cancer-Pipeline by Aphios Corporation, H1 2016 83

Colon Cancer-Pipeline by Aposense Ltd., H1 2016 84

Colon Cancer-Pipeline by Aptose Biosciences Inc., H1 2016 85

Colon Cancer-Pipeline by Asana BioSciences, LLC, H1 2016 86

Colon Cancer-Pipeline by AstraZeneca Plc, H1 2016 87

Colon Cancer-Pipeline by Aurigene Discovery Technologies Limited, H1 2016 88

Colon Cancer-Pipeline by BCN Biosciences L.L.C., H1 2016 89

Colon Cancer-Pipeline by Bio-Path Holdings, Inc., H1 2016 90

Colon Cancer-Pipeline by Biogazelle, H1 2016 91

Colon Cancer-Pipeline by Bioncotech Therapeutics S.L., H1 2016 92

Colon Cancer-Pipeline by Blirt S.A., H1 2016 93

Colon Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2016 94

Colon Cancer-Pipeline by Can-Fite BioPharma Ltd., H1 2016 95

Colon Cancer-Pipeline by Celprogen, Inc., H1 2016 96

Colon Cancer-Pipeline by Celyad SA, H1 2016 97

Colon Cancer-Pipeline by Chiome Bioscience, Inc., H1 2016 98

Colon Cancer-Pipeline by Critical Outcome Technologies Inc., H1 2016 99

Colon Cancer-Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016 100

Colon Cancer-Pipeline by CytomX Therapeutics, Inc., H1 2016 101

Colon Cancer-Pipeline by Cytune Pharma SAS, H1 2016 102

Colon Cancer-Pipeline by CZ BioMed Corp, H1 2016 103

Colon Cancer-Pipeline by DEKK-TEC, Inc., H1 2016 104

Colon Cancer-Pipeline by Digna Biotech, S.L., H1 2016 105

Colon Cancer-Pipeline by Eli Lilly and Company, H1 2016 106

Colon Cancer-Pipeline by EntreChem, S.L., H1 2016 107

Colon Cancer-Pipeline by EnzymeBioSystems, H1 2016 108

Colon Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 109

Colon Cancer-Pipeline by GlycaNova Norway AS, H1 2016 110

Colon Cancer-Pipeline by Halozyme Therapeutics, Inc., H1 2016 111

Colon Cancer-Pipeline by Heat Biologics, Inc., H1 2016 112

Colon Cancer-Pipeline by Helix BioPharma Corp., H1 2016 113

Colon Cancer-Pipeline by Histogen, Inc., H1 2016 114

Colon Cancer-Pipeline by Horizon Pharma Plc, H1 2016 115

Colon Cancer-Pipeline by Huperion Sarl, H1 2016 116

Colon Cancer-Pipeline by Idera Pharmaceuticals, Inc., H1 2016 117

Colon Cancer-Pipeline by Ignyta, Inc., H1 2016 118

Colon Cancer-Pipeline by Immunome Inc., H1 2016 119

Colon Cancer-Pipeline by Immunomedics, Inc., H1 2016 120

Colon Cancer-Pipeline by Immunotope, Inc., H1 2016 121

Colon Cancer-Pipeline by Immupharma Plc, H1 2016 122

Colon Cancer-Pipeline by IMPACT Therapeutics, Inc., H1 2016 123

Colon Cancer-Pipeline by Incuron, LLC, H1 2016 124

Colon Cancer-Pipeline by Infinity Pharmaceuticals, Inc., H1 2016 125

Colon Cancer-Pipeline by Inflection Biosciences Limited, H1 2016 126

Colon Cancer-Pipeline by Innopharmax Inc., H1 2016 127

Colon Cancer-Pipeline by Intezyne, Inc, H1 2016 128

Colon Cancer-Pipeline by Ironwood Pharmaceuticals, Inc., H1 2016 129

Colon Cancer-Pipeline by Jasco Pharmaceuticals, LLC., H1 2016 130

Colon Cancer-Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2016 131

Colon Cancer-Pipeline by JW Pharmaceutical Corporation, H1 2016 132

Colon Cancer-Pipeline by Karyopharm Therapeutics, Inc., H1 2016 133

Colon Cancer-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 134

Colon Cancer-Pipeline by Les Laboratoires Servier SAS, H1 2016 135

Colon Cancer-Pipeline by Lipocure Ltd., H1 2016 136

Colon Cancer-Pipeline by LipoMedix Pharmaceutical Inc., H1 2016 137

Colon Cancer-Pipeline by Lupin Limited, H1 2016 138

Colon Cancer-Pipeline by Lymphocyte Activation Technologies, S.A., H1 2016 139

Colon Cancer-Pipeline by MabVax Therapeutics Holdings, Inc., H1 2016 140

Colon Cancer-Pipeline by MacroGenics, Inc., H1 2016 141

Colon Cancer-Pipeline by MaxiVAX SA, H1 2016 142

Colon Cancer-Pipeline by Meabco A/S, H1 2016 143

Colon Cancer-Pipeline by Molecular Targeting Technologies, Inc., H1 2016 144

Colon Cancer-Pipeline by MolMed S.p.A., H1 2016 145

Colon Cancer-Pipeline by Monopar Therapeutics LLC, H1 2016 146

Colon Cancer-Pipeline by Multimmune GmbH, H1 2016 147

Colon Cancer-Pipeline by NormOxys, Inc., H1 2016 148

Colon Cancer-Pipeline by Novartis AG, H1 2016 149

Colon Cancer-Pipeline by Omeros Corporation, H1 2016 150

Colon Cancer-Pipeline by Omnitura Therapeutics Inc., H1 2016 151

Colon Cancer-Pipeline by OncoVista Innovative Therapies, Inc., H1 2016 152

Colon Cancer-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 153

Colon Cancer-Pipeline by Orega Biotech SAS, H1 2016 154

Colon Cancer-Pipeline by OSE Immunotherapeutics, H1 2016 155

Colon Cancer-Pipeline by Panacea Pharmaceuticals, Inc., H1 2016 156

Colon Cancer-Pipeline by PharmaCyte Biotech, Inc., H1 2016 157

Colon Cancer-Pipeline by Pharminox Limited, H1 2016 158

Colon Cancer-Pipeline by Philogen S.p.A., H1 2016 159

Colon Cancer-Pipeline by Pique Therapeutics, H1 2016 160

Colon Cancer-Pipeline by Plexxikon Inc., H1 2016 161

Colon Cancer-Pipeline by Provecs Medical GmbH, H1 2016 162

Colon Cancer-Pipeline by Provectus Biopharmaceuticals, Inc., H1 2016 163

Colon Cancer-Pipeline by Qu Biologics Inc., H1 2016 164

Colon Cancer-Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 165

Colon Cancer-Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016 166

Colon Cancer-Pipeline by Rgenix, Inc., H1 2016 167

Colon Cancer-Pipeline by Sareum Holdings Plc, H1 2016 168

Colon Cancer-Pipeline by Savoy Pharmaceuticals, Inc., H1 2016 169

Colon Cancer-Pipeline by Sellas Inc., H1 2016 170

Colon Cancer-Pipeline by Sigma-Tau S.p.A., H1 2016 171

Colon Cancer-Pipeline by Sirnaomics, Inc., H1 2016 172

Colon Cancer-Pipeline by Somantix B.V., H1 2016 173

Colon Cancer-Pipeline by Sorrento Therapeutics, Inc., H1 2016 174

Colon Cancer-Pipeline by Sphaera Pharma Pvt. Ltd., H1 2016 175

Colon Cancer-Pipeline by Starpharma Holdings Limited, H1 2016 176

Colon Cancer-Pipeline by Synergys Biotherapeutics, Inc., H1 2016 177

Colon Cancer-Pipeline by Synta Pharmaceuticals Corp., H1 2016 178

Colon Cancer-Pipeline by Taiwan Liposome Company, Ltd., H1 2016 179

Colon Cancer-Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 180

Colon Cancer-Pipeline by Theryte Limited, H1 2016 181

Colon Cancer-Pipeline by Transgene Biotek Limited, H1 2016 182

Colon Cancer-Pipeline by TVAX Biomedical, Inc., H1 2016 183

Colon Cancer-Pipeline by Tyg Oncology Ltd., H1 2016 184

Colon Cancer-Pipeline by Vaccinogen, Inc., H1 2016 185

Colon Cancer-Pipeline by Vault Pharma Inc., H1 2016 186

Colon Cancer-Pipeline by Vaximm AG, H1 2016 187

Colon Cancer-Pipeline by VG Life Sciences, Inc., H1 2016 188

Colon Cancer-Pipeline by Yakult Honsha Co., Ltd., H1 2016 189

Colon Cancer-Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2016 190

Colon Cancer-Pipeline by ZIOPHARM Oncology, Inc., H1 2016 191

Assessment by Monotherapy Products, H1 2016 192

Assessment by Combination Products, H1 2016 193

Number of Products by Stage and Target, H1 2016 195

Number of Products by Stage and Mechanism of Action, H1 2016 205

Number of Products by Stage and Route of Administration, H1 2016 213

Number of Products by Stage and Molecule Type, H1 2016 215

Colon Cancer-Dormant Projects, H1 2016 641

Colon Cancer-Dormant Projects (Contd..1), H1 2016 642

Colon Cancer-Dormant Projects (Contd..2), H1 2016 643

Colon Cancer-Dormant Projects (Contd..3), H1 2016 644

Colon Cancer-Dormant Projects (Contd..4), H1 2016 645

Colon Cancer-Dormant Projects (Contd..5), H1 2016 646

Colon Cancer-Dormant Projects (Contd..6), H1 2016 647

Colon Cancer-Dormant Projects (Contd..7), H1 2016 648

Colon Cancer-Dormant Projects (Contd..8), H1 2016 649

Colon Cancer-Dormant Projects (Contd..9), H1 2016 650

Colon Cancer-Dormant Projects (Contd..10), H1 2016 651

Colon Cancer-Dormant Projects (Contd..11), H1 2016 652

Colon Cancer-Dormant Projects (Contd..12), H1 2016 653

Colon Cancer-Dormant Projects (Contd..13), H1 2016 654

Colon Cancer-Dormant Projects (Contd..14), H1 2016 655

Colon Cancer-Dormant Projects (Contd..15), H1 2016 656

Colon Cancer-Dormant Projects (Contd..16), H1 2016 657

Colon Cancer-Dormant Projects (Contd..17), H1 2016 658

Colon Cancer-Discontinued Products, H1 2016 659

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

ACF Pharmaceuticals, LLC

Adgero Biopharmaceuticals, Inc.

Aduro BioTech, Inc.

Advanced Proteome Therapeutics Corporation

Advenchen Laboratories, LLC

Agenus, Inc.

AGV Discovery, SAS

AIMM Therapeutics B.V.

Ambrx, Inc.

Anavex Life Sciences Corp.

AndroScience Corporation

Aphios Corporation

Aposense Ltd.

Aptose Biosciences Inc.

Asana BioSciences, LLC

AstraZeneca Plc

Aurigene Discovery Technologies Limited

BCN Biosciences L.L.C.

Bio-Path Holdings, Inc.

Biogazelle

Bioncotech Therapeutics S.L.

Blirt S.A.

Boehringer Ingelheim GmbH

Can-Fite BioPharma Ltd.

Celprogen, Inc.

Celyad SA

Chiome Bioscience, Inc.

Critical Outcome Technologies Inc.

Cyclacel Pharmaceuticals, Inc.

CytomX Therapeutics, Inc.

Cytune Pharma SAS

CZ BioMed Corp

DEKK-TEC, Inc.

Digna Biotech, S.L.

Eli Lilly and Company

EntreChem, S.L.

EnzymeBioSystems

F. Hoffmann-La Roche Ltd.

GlycaNova Norway AS

Halozyme Therapeutics, Inc.

Heat Biologics, Inc.

Helix BioPharma Corp.

Histogen, Inc.

Horizon Pharma Plc

Huperion Sarl

Idera Pharmaceuticals, Inc.

Ignyta, Inc.

Immunome Inc.

Immunomedics, Inc.

Immunotope, Inc.

Immupharma Plc

IMPACT Therapeutics, Inc.

Incuron, LLC

Infinity Pharmaceuticals, Inc.

Inflection Biosciences Limited

Innopharmax Inc.

Intezyne, Inc

Ironwood Pharmaceuticals, Inc.

Jasco Pharmaceuticals, LLC.

Jiangsu Kanion Pharmaceutical Co., Ltd.

JW Pharmaceutical Corporation

Karyopharm Therapeutics, Inc.

Kyowa Hakko Kirin Co., Ltd.

Les Laboratoires Servier SAS

Lipocure Ltd.

LipoMedix Pharmaceutical Inc.

Lupin Limited

Lymphocyte Activation Technologies, S.A.

MabVax Therapeutics Holdings, Inc.

MacroGenics, Inc.

MaxiVAX SA

Meabco A/S

Molecular Targeting Technologies, Inc.

MolMed S.p.A.

Monopar Therapeutics LLC

Multimmune GmbH

NormOxys, Inc.

Novartis AG

Omeros Corporation

Omnitura Therapeutics Inc.

OncoVista Innovative Therapies, Inc.

Ono Pharmaceutical Co., Ltd.

Orega Biotech SAS

OSE Immunotherapeutics

Panacea Pharmaceuticals, Inc.

PharmaCyte Biotech, Inc.

Pharminox Limited

Philogen S.p.A.

Pique Therapeutics

Plexxikon Inc.

Provecs Medical GmbH

Provectus Biopharmaceuticals, Inc.

Qu Biologics Inc.

Regeneron Pharmaceuticals, Inc.

Rexahn Pharmaceuticals, Inc.

Rgenix, Inc.

Sareum Holdings Plc

Savoy Pharmaceuticals, Inc.

Sellas Inc.

Sigma-Tau S.p.A.

Sirnaomics, Inc.

Somantix B.V.

Sorrento Therapeutics, Inc.

Sphaera Pharma Pvt. Ltd.

Starpharma Holdings Limited

Synergys Biotherapeutics, Inc.

Synta Pharmaceuticals Corp.

Taiwan Liposome Company, Ltd.

Takeda Pharmaceutical Company Limited

Theryte Limited

Transgene Biotek Limited

TVAX Biomedical, Inc.

Tyg Oncology Ltd.

Vaccinogen, Inc.

Vault Pharma Inc.

Vaximm AG

VG Life Sciences, Inc.

Yakult Honsha Co., Ltd.

Zensun (Shanghai) Sci & Tech Co., Ltd.

ZIOPHARM Oncology, Inc.

Colon Cancer Therapeutic Products under Development, Key Players in Colon Cancer Therapeutics, Colon Cancer Pipeline Overview, Colon Cancer Pipeline, Colon Cancer Pipeline Assessment

select a license

Single User License
USD 2500 INR 160650
Site License
USD 5000 INR 321300
Corporate User License
USD 7500 INR 481950

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com